Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-06-05
2007-06-05
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
10719547
ABSTRACT:
A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
REFERENCES:
patent: 6074865 (2000-06-01), Kelly et al.
patent: 6455509 (2002-09-01), Kochel et al.
patent: WO 00/57907 (2000-10-01), None
Angsubhakorn, S. et al. 1994 “Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses inMacaca fascicularis,” Southeast Asian J. Trop. Med. Public Health25:554-559.
Bancroft W.H. et al. 1981 “Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients,”Infect. Immun. 31:698-703.
Bancroft, W.H. et al. 1984 “Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers.”J. Infect. Dis. 149:1005-1010.
Bhamarapravati, N. et al. 2000 “Live attenuated tetravalent dengue vaccine.”Vaccine18(Suppl. 2):44-47.
Bhamarapravati, N. et al. 1997 Live attenuated tetravalent dengue vaccine, p. 367-377. In D. J. Gubler, and G. Kuno (ed.),Dengue and Dengue Hemorrhagic Fever. CAB International, New York, N.Y.
Bhamarpravati N. et al. 1987 “Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers,”Bull World Health Organ. 65:189-195.
Blaney J.E. Jr., et al. 2001 “Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.”J. Virol. 75:9731-9740.
Blok, J. et al. 1992 “Comparison of a dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses.”Virology187:573-590.
Bray, M. et al. 1996 “Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge,”J. Virol. 70:4162-4166.
Bray, M. et al. 1991 “Construction of intertypic chimeric dengue viruses by substitution of structural protein genes,”PNAS USA88:10342-10346.
Burke, D.S. et al. 1988 “A prospective study of dengue infections in Bangkok.”Am. J. Trop. Med. Hyg. 38:172-180.
Butrapet, S. et al. 2000 “Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3.”J. Virol. 74:3011-3019.
CDC, 2000 “Public Health Dispatch: Outbreak of poliomyelitis—Dominican Republic and Haiti, 2000”MMWR Morb. Mortal Wkly. Rep. 49:1094-1104.
Chambers, T.J. et al. 1999 “Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties,”J. Virol. 73:3095-3101.
Chang, G.-J. 1997 Molecular biology of dengue viruses, p. 175-198. In D. J. Gubler, and G. Kuno (ed.),Dengue and Dengue Hemmorrhagic Fever. CAB International, New York, N.Y.
Chen, W. et al. 1995 “Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice,”J. Virol. 69:5186-5190.
Cole, G.A. et al. 1969 “Pathogenesis of type 1 dengue virus infection in suckling, weanling and adult mice. 1. The relation of virus replication to interferon and antibody formation.”Am. J. Epidemiol. 89:669-680.
Cole, G.A. et al. 1973 “Pathogenesis of type 1 dengue virus infection in suckling, weaning and adult mice. II. Immunofluorescent and histological studies.”J. Comp. Pathol. 83:243-252.
Couvelard, A. et al. 1999 “Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis.”Hum. Pathol. 30:1106-1110.
Dunster, L.M. et al. 1999 “Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus.”Virology261:309-318.
Durbin A.P. et al. 2001 “Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion and its 3′-untranslated region.”Am. J. Trop. Med. Hyg. 65:405-13.
Eckels, K.H. et al. 1980 “Dengue-2 vaccine: preparation from a small-plaque virus clone.”Infect. Immun. 27:175-180.
Eckels, K.H. et al. 1984 “Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells.”A. J. Trop. Med. Hyg. 33:684-689.
Edelman, R. et al. 1994 “A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.”J. Infect. Dis. 170:1448-1455.
Gubler, D.J. et al. 1998 “Dengue and dengue hemorrhagic fever,”Clin. Microbiol. Rev. 11:480-496.
Gubler, D. J. 1999 “Impact of dengue/dengue hemmorrhagic fever on the developing world.”Adv. Virus Res. 53:35-70.
Guirakhoo, F. et al. 2000 “Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.”J. Virol. 74:5477-5485.
Halstead, S.B. et al. 1977 “Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection.”J. Exp. Med. 146:218-229.
Halstead, S.B. et al. 1969 “Dengue and chikungunya virus infection in man in Thailand, 1962-1964. IV. Epidemiologic studies in the Bangkok metropolitan area.”Am. J. Trop. Med. Hyg. 18:997-1021.
Hoke, C.H. Jr. et al. 1990. “Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans,”Am. J. Trop. Med. Hyg. 43:219-226.
Holbrook, M.R. et al. 2000 “The French neurotropic vaccine strain of yellow fever virus accumulates mutations slowly during passage in cell culture.”Virus Res. 69:31-39.
Huang, C.Y. et al. 2000 “Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.”J. Virol. 74:3020-3028.
Huerre, M.R. et al. 2001 “Liver histophathology and biological correlates in five cases of fatal dengue fever in Vietnamese children.”Virchows Arch. 438:107-115.
Igarashi, A. 1997 “Impact of dengue virus infection and its control,”FEMS Immunol. Med. Microbiol. 18:291-300.
Innis, B.L. 1995 Dengue and dengue hemorrhagic fever, p. 103-146. In J. S. Porterfield (ed.),Exotic Viral Infections. Chapman and Hall, London, United Kingdom.
Innis, B L. et al. 1988 “Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation.”J. Infect. Dis. 158:876-880.
Jennings, A.D. et al. 1994 “Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis.”J. Infect. Dis. 169:512-518.
Kalayanarooj, S. et al. 1997 “Early clinical and laboratory indicators of acute dengue illness.”J. Infect. Dis. 176:313-321.
Kanesa-thasan, N. et al. 2001 “Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.”Vaccine19:3179-3188.
Kraiselburd E. et al. 1985 “Quantity of dengue virus required to infect rhesus monkeys,”Trans. R. Soc. Trop. Med. Hyg. 79:248-251.
Kuo, C.H. et al. 1992 “Liver biochemical tests and dengue fever.”Am. J. Trop. Med. Hyg. 47:265-270.
Kurane, I. et al. 1990 “Dengue-2 virus infection of human mononuclear cell lines and establishment of persistent infections.”Arch. Virol. 110:91-101.
Lai, C.J. et al. 1991 “Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus,”Proc Natl Acad Sci USA88:5139-5143.
Lee, E. et al. 1997 “Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein.”Virology232:281-290.
Libraty, D.H. et al. 2001 “Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for dis
Blaney Joseph E.
Hanley Kathryn A.
Murphy Brian R.
Whitehead Stephen S.
Knobbe Martens Olson & Bear LLP
Parkin Jeffrey S.
The United States of America, as represented by the Secretary, D
LandOfFree
Development of mutations useful for attenuating dengue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Development of mutations useful for attenuating dengue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Development of mutations useful for attenuating dengue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873170